Company research / STLN
Starling Oncology, Inc. (STLN)
- Sector Services
- Incorporated DE
- Fiscal year ends Dec 31
For the year ended 2025-12-31, Starling Oncology, Inc. reported revenue of $502.73M. Revenue grew 27.8% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $587.24M.
Key ratios (year ended 2025-12-31)
-7.2%
Operating margin
-12.1%
Net margin
27.8%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.